Skip header and navigation

65 records – page 1 of 7.

Mueller, M.; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 21; Document no.: EOC011901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 31 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc247

Azizian, A; Groot, G; Mueller, M; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 24; Document no.: EOC011901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc249

Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 04. Document no.: EOC220501 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc474

Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc477

Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 10 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc478

Dalidowicz, M; Miller, L. Is there any association or links between COVID and interferonopathy or polymyositis? 2022 May 09, Document no.: EOC220502 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc476

Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Miller, L. Is there any association or links between COVID and interferonopathy or polymyositis? 2022 May 11, Document no.: EOC220502 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc481

Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Miller, L. Is there any association or links between COVID and interferonopathy or polymyositis? 2022 May 11, Document no.: EOC220502 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 7 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc482

Badea, A; Reeder, B; Groot, G; Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive an mRNA vaccine booster/3rd dose? 2022 Feb 04, Document no.: EOC220102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc436

Badea, A; Reeder, B; Groot, G; Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Feb 04, Document no.: EOC220102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 8 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc438

65 records – page 1 of 7.